Navigation Links
OncoGenex in Medical News

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company

...in net proceeds from the sale of common stock to a subsidiary of Cadila Pharmaceuticals as part of a new strategic alliance. On July 20, 2009, oncogenex Pharmaceuticals, Inc. raised approximately $9 million in net proceeds from a direct common stock offering to certain institutional investors. O...

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

...-427 are antisense drugs co-discovered by Isis and oncogenex (Nasdaq: OGXI ) and Isis licensed its rights to OGX-011 to oncogenex Pharmaceuticals, Inc. In addition, new results f...s with cancer were also presented. Both Lilly and oncogenex are also developing additional anti-cancer drugs i...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

...hat showed iCo-007 appears to be well tolerated and demonstrates promising signs of activity in patients with diffuse diabetic macular edema. oncogenex reached an agreement with the FDA on the design of a second Phase 3 registration trial of OGX-011 that features durable pain palliation as the primary...

Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

...the annual ASCO meeting in Chicago. Both Lilly and oncogenex are developing additional anticancer drugs discove... antisense drugs being developed by Isis' partners oncogenex and Lilly continue to demonstrate the potential of antisense technology to treat multiple cancers. oncogenex presented Phase 2 data on OGX-011 demonstrating be...

Isis Reports Financial Results and Highlights for First Quarter of 2008

... -- Isis received a $2 million milestone payment with the selection of an antisense drug candidate to advance into development. o oncogenex reported encouraging Phase 2 data of OGX-011, an antisense drug in clinical studies in patients with advanced prostate or lung cancers. ...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...rugs discovered by Isis to treat cancer. * oncogenex reported encouraging Phase 2 data for OGX-011, an ...y agents alone, based on historical controls. * oncogenex initiated Phase 1 clinical studies of OGX-427, an ...ntial of antisense drugs. Already this year, oncogenex reported Phase 2 results for OGX-011 in prostate ...
OncoGenex in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ned $1.4 million of revenue when Isis sold drug to oncogenex Pharmaceuticals, Inc. Isis' re...cal Oncology (ASCO) annual meeting. oncogenex reported results of a randomized Phase 2 trial of ...for patients treated with docetaxel alone. oncogenex reported that OGX-427 was well tolerated as a mono...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

...icals, Inc. (Nasdaq: ISIS ) announced today that oncogenex Pharmaceuticals, Inc. provided positive survival r...he latest results from OGX-011 and look forward to oncogenex announcing the full results of the study next year...llow-up of approximately 30 months for both arms. oncogenex indicates that additional survival updates will be...

OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting

... VANCOUVER, April 17, 2007 /PRNewswire/ - oncogenex Technologies Inc. announced today data from a Phas...ing chemotherapy, and facilitate tumor cell death. oncogenex is developing OGX-011 in collaboration with Isis P...rt provided by OncoGenex Technologies Inc. About oncogenex ...

OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

...ARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/ - oncogenex Technologies Inc. and Isis Pharmaceuticals, Inc. t...ing chemotherapy, and facilitate tumor cell death. oncogenex and Isis are collaborating on development of OGX-011. About oncogenex ...
OncoGenex in Biological Technology

FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011

BOTHELL, WA and VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive meta...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI' Implements immediate restructuring program, which extends cash runway while focusing on clinical pipeline programs BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceut...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

- Combined Company Will Have Three Oncology Products in Clinic - - Lead Candidate Targets Hormone Refractory Prostate and Non-Small Cell Lung Cancers - - Conference Call to be Held Wednesday, May 28th, at 11:00 a.m. Pacific Time...

OncoGenex Reports Second Quarter 2009 Financial Results

...WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company...ing consolidated results reflect the operations of oncogenex Technologies Inc. ("OncoGenex Technologies") prior...s, Inc. ("Sonus"), and the consolidated results of oncogenex thereafter. The loss attributable to common shar...

OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results

... WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals (NASDAQ: OGXI ) announced today ...ter financial results on Thursday, August 6, 2009. oncogenex will host a conference call and live webcast at 4:... be accessed on the Investor Relations page of the oncogenex Web site at www.oncogenex.com . Alternatively, yo...

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

...WA and VANCOUVER, July 24 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ... purposes. The shares of common stock offered by oncogenex in this transaction were offered and sold pursuant...ission's web site at http://www.sec.gov , or from oncogenex Pharmaceuticals, Inc., 1522 217th Pl. SE, Suite 10...

OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock

...WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ...ected to provide gross proceeds of $9.5 million to oncogenex before deducting costs associated with the offerin... 24, 2009. The shares of common stock offered by oncogenex in this transaction will be issued pursuant to the...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...g Receives FDA Approval for Degarelix in Prostate Cancer II-53 Isis and oncogenex Reveals Positive results of OGX-011 Molecule in HRPC II-53 Antisoma... BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko II-87 oncogenex and Isis Pharmaceuticals Expand Partnership II-87 Caprion and AstraZene...

OncoGenex Pharmaceuticals Added to Russell Indexes

...A, and VANCOUVER, June 30 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ), a biophar...l.com/Indexes/performance/default.asp . About oncogenex oncogenex is a biopharmaceutical company committed to the de...

OncoGenex Pharmaceuticals Files Shelf Registration Statement

...WA and VANCOUVER, June 26 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ...o fund our Phase 3 clinical trials for OGX-011." oncogenex elected to terminate its previous shelf registrati...ent and MJDS prospectus, respectively, will permit oncogenex Pharmaceuticals to sell, from time to time over a ...
Other Tags
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2
Other Contents